New Pfizer/BioNTech COVID-19 Vaccine Data Confirm Prior Results, Show T-Cell Boost

While data from small trials are difficult to compare, it appears that T-cell responses to BNT162b1 may be stronger than those reported so far for Moderna’s competing mRNA-based vaccine. 

Vaccination against the new Corona Virus SARS-CoV-2: A syringe being drawn up with SARS-CoV-2 vaccination.
Pfizer and BioNTech report results from a second Phase I/II study, which was conducted in Germany • Source: Shutterstock

Pfizer Inc. and BioNTech SE released Phase I/II results for their messenger RNA (mRNA)-based COVID-19 vaccine candidate BNT162b1, from a clinical trial conducted in Germany, that showed T-cell responses that may be stronger than those observed with a competing mRNA vaccine from Moderna, Inc. The data are also consistent with neutralizing antibody data reported previously from a US study.

Pfizer and BioNTech reported results on 20 July from 60 German trial participants, including 12 patients each injected with 1mcg,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from COVID-19

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By 

One Phase III trial hits but a second study misses by a mile.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By 

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Arcturus and CSL Take on Pfizer With Longer-Lasting COVID Vaccine

 
• By 

Kostaive is the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission and could provide serious competition to Pfizer/BioNTech's Comirnaty and Moderna's Spikevax.

Under-Pressure Moderna Banks $590m To Speed Up Bird Flu Vaccine

 
• By 

A week after a downbeat forecast at J.P. Morgan Healthcare Conference, the US mRNA specialist has pocketed another sizeable sum from the US Department of Health and Human Services to accelerate development of an H5N1 mRNA pandemic influenza vaccine.

More from Scrip

Pfizer’s Hympavzi Poised For Broader Hemophilia Label

 

The drugmaker announced positive topline results for the drug in hemophilia A and B patients with inhibitors, on top of the existing approval for patients without inhibitors.

BIO Finance Trends: Drug Developers Face Harsh Realities As Funding Constraints Continue

 
• By 

Financial markets were expected to loosen up in 2025, but BIO convention attendees indicated that conditions have worsened this year, so public and private firms are making tough choices.

Pharma Growth And Biotech Squeeze Will Shape Sector To 2030, Evaluate Forecasts

 

Evaluate’s five-year forecast sees steady growth for big pharma despite recent political turmoil but tougher times ahead for the ‘have nots’ of biotech.